Brexit’s Effect on U.K. Life Sciences
Making the Nation a One-stop Regulatory Engine for Innovation
Vertex’s David Altshuler Humanizes Drug Discovery
Lessons from Vertex’s Small Molecule Drug Development Program for Cystic Fibrosis
10 Takeover Targets to Watch This Fall
Pace of Biopharma M&A Slows from First Half Stampede of Deals
Bioprocessing Companies Push Limits of Upstream Technologies
Goal Is to Maximize Efficiency in Bioprocess Operations
For full access to this article login to GEN Select now.
Managing Biosimilars Is Like Herding Copycats
Developers and Regulators Are Attending to Naming Conventions and Equivalence Testing Assays
- Biosimilars, or copycats of biologic drugs, stray from clearly defined categories. Each biosimilar comes from a unique biomanufacturing environment and, consequently, possesses unique chemical attributes, which may or may not prove to be clinically relevant—most likely not (but worth checking). Moreover, each biosimilar may go its own way, ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.